Targeting mitochondria metabolism for cancer therapy

Nature Chemical Biology

Volumn 11, Issue 1, 2015, Pages 9-15

  Weinberg, Samuel E ^a   Chandel, Navdeep S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AUTOPHAGY; BIOENERGY; CANCER THERAPY; CELL ORGANELLE; CELL PROLIFERATION; CITRIC ACID CYCLE; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; ANIMAL; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84927133194     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1712     Document Type: Review

References (102)

1. Bonnet, S. et al. A mitochondria-K channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11, 37-51 (2007)
2. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956)
3. Ames, B.N., Shigenaga, M.K. & Hagen, T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA 90, 7915-7922 (1993)
4. Koppenol, W.H., Bounds, P.L. & Dang, C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325-337 (2011)
5. Cross, C.E. et al. Oxygen radicals and human disease. Ann. Intern. Med. 107, 526-545 (1987)
6. Weinhouse, S. On respiratory impairment in cancer cells. Science 124, 267-269 (1956)
7. Weinhouse, S., Millington, R.H. & Wenner, C.E. Metabolism of neoplastic tissue. I. The oxidation of carbohydrate and fatty acids in transplanted tumors. Cancer Res. 11, 845-850 (1951).
8. Wenner, C.E., Spirtes, M.A. & Weinhouse, S. Metabolism of neoplastic tissue. II. A survey of enzymes of the citric acid cycle in transplanted tumors. Cancer Res. 12, 44-49 (1952).
9. Weinhouse, S. Studies on the fate of isotopically labeled metabolites in the oxidative metabolism of tumors. Cancer Res. 11, 585-591 (1951).
10. Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 107, 8788-8793 (2010)
11. Fogal, V. et al. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol. Cell. Biol. 30, 1303-1318 (2010)
12. Guo, J.Y. et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 25, 460-470 (2011)
13. Wellen, K.E. et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076-1080 (2009)
14. Kaelin, W.G. Jr. & McKnight, S.L. Influence of metabolism on epigenetics and disease. Cell 153, 56-69 (2013)
15. Sena, L.A. & Chandel, N.S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 48, 158-167 (2012)
16. Pagliarini, D.J. et al. Involvement of a mitochondrial phosphatase in the regulation of ATP production and insulin secretion in pancreatic β cells. Mol. Cell 19, 197-207 (2005)
17. Acin-Perez, R., Gatti, D.L., Bai, Y. & Manfredi, G. Protein phosphorylation and prevention of cytochrome oxidase inhibition by ATP: coupled mechanisms of energy metabolism regulation. Cell Metab. 13, 712-719 (2011)
18. Huang, L.J. et al. NH2-terminal targeting motifs direct dual specificity A-kinase-anchoring protein 1 (D-AKAP1) to either mitochondria or endoplasmic reticulum. J. Cell Biol. 145, 951-959 (1999)
19. Seth, R.B., Sun, L., Ea, C.K. & Chen, Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF 3. Cell 122, 669-682 (2005)
20. Chandel, N.S. Mitochondria as signaling organelles. BMC Biol. 12, 34 (2014)
21. Ward, P.S. & Thompson, C.B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21, 297-308 (2012)
22. Lunt, S.Y. & Vander Heiden, M.G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441-464 (2011)
23. Dang, C.V. Links between metabolism and cancer. Genes Dev. 26, 877-890 (2012)
24. Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311-321 (2005)
25. DeBerardinis, R.J. & Cheng, T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313-324 (2010)
26. Schieber, M. & Chandel, N.S. ROS function in redox signaling and oxidative stress. Curr. Biol. 24, R453-R462 (2014)
27. Gorrini, C., Harris, I.S. & Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931-947 (2013)
28. Fan, J. et al. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510, 298-302 (2014)
29. Lewis, C.A. et al. Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol. Cell 55, 253-263 (2014)
30. Yang, M., Soga, T. & Pollard, P.J. Oncometabolites: linking altered metabolism with cancer. J. Clin. Invest. 123, 3652-3658 (2013)
31. Wallace, D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39, 359-407 (2005)
32. Mullen, A.R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385-388 (2012).
33. Wise, D.R. et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA 108, 19611-19616 (2011)
34. Metallo, C.M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384 (2012).
35. Sullivan, L.B. et al. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol. Cell 51, 236-248 (2013)
36. Guzy, R.D., Sharma, B., Bell, E., Chandel, N. & Schumacker, P. Loss of the SdhB, but not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol. Cell. Biol. 28, 718-731 (2008)
37. Woo, D.K. et al. Mitochondrial genome instability and ROS enhance intestinal tumorigenesis in APC(Min/+) mice. Am. J. Pathol. 180, 24-31 (2012)
38. Petros, J.A. et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl. Acad. Sci. USA 102, 719-724 (2005)
39. Ishikawa, K. et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320, 661-664 (2008)
40. Porporato, P.E. et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 8, 754-766 (2014)
41. Wallace, D.C. Mitochondria and cancer. Nat. Rev. Cancer 12, 685-698 (2012)
42. Zu, X.L. & Guppy, M. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 313, 459-465 (2004)
43. Fan, J. et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol. Syst. Biol. 9, 712 (2013)
44. Jain, R.K., Munn, L.L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nat. Rev. Cancer 2, 266-276 (2002)
45. Gatenby, R.A. & Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899 (2004)
46. Rumsey, W.L., Schlosser, C., Nuutinen, E.M., Robiolio, M. & Wilson, D.F. Cellular energetics and the oxygen dependence of respiration in cardiac myocytes isolated from adult rat. J. Biol. Chem. 265, 15392-15402 (1990).
47. Caro, P. et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22, 547-560 (2012)
48. Vazquez, F. et al. PGC1a expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23, 287-301 (2013)
49. Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1a and MITF. Cancer Cell 23, 302-315 (2013)
50. Engelman, J.A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008)
51. Bailey, C.J. & Turner, R.C. Metformin. N. Engl. J. Med. 334, 574-579 (1996)
52. Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R. & Morris, A.D. Metformin and reduced risk of cancer in diabetic patients. Br. Med. J. 330, 1304-1305 (2005)
53. Dowling, R.J., Niraula, S., Stambolic, V. & Goodwin, P.J. Metformin in cancer: translational challenges. J. Mol. Endocrinol. 48, R31-R43 (2012)
54. Buzzai, M. et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752 (2007)
55. Memmott, R.M. et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. (Phila.) 3, 1066-1076 (2010)
56. Tomimoto, A. et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 99, 2136-2141 (2008)
57. Pollak, M. Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat. Med. 20, 591-593 (2014)
58. Birsoy, K., Sabatini, D.M. & Possemato, R. Untuning the tumor metabolic machine: targeting cancer metabolism: a bedside lesson. Nat. Med. 18, 1022-1023 (2012)
59. Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 12, 159-169 (2012).
60. El-Mir, M.Y. et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223-228 (2000)
61. Owen, M.R., Doran, E. & Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607-614 (2000)
62. Bridges, H.R., Jones, A.J., Pollak, M.N. & Hirst, J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 462, 475-487 (2014)
63. Wheaton, W.W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3, e02242 (2014)
64. Fendt, S.M. et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 73, 4429-4438 (2013)
65. Janzer, A. et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc. Natl. Acad. Sci. USA 111, 10574-10579 (2014)
66. Hardie, D.G. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62, 2164-2172 (2013)
67. Storozhuk, Y. et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br. J. Cancer 108, 2021-2032 (2013)
68. Emami Riedmaier, A., Fisel, P., Nies, A.T., Schaeffeler, E. & Schwab, M. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol. Sci. 34, 126-135 (2013)
69. Appleyard, M.V. et al. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br. J. Cancer 106, 1117-1122 (2012)
70. Birsoy, K. et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508, 108-112 (2014)
71. Shackelford, D.B. et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23, 143-158 (2013)
72. Yuan, P. et al. Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma. Proc. Natl. Acad. Sci. USA 110, 18226-18231 (2013)
73. Zhang, X. et al. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun. 5, 3295 (2014).
74. Škrtić, M. et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674-688 (2011)
75. Chae, Y.C. et al. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell 22, 331-344 (2012)
76. Hensley, C.T., Wasti, A.T. & DeBerardinis, R.J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 123, 3678-3684 (2013)
77. Wise, D.R. et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 105, 18782-18787 (2008)
78. Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765 (2009)
79. Gaglio, D. et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7, 523 (2011)
80. Wang, J.B. et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207-219 (2010)
81. Le, A. et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15, 110-121 (2012)
82. Thornburg, J.M. et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 10, R84 (2008)
83. Qing, G. et al. ATF4 Regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 22, 631-644 (2012)
84. Strohecker, A.M. et al. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 3, 1272-1285 (2013)
85. Bjelakovic, G. & Gluud, C. Surviving antioxidant supplements. J. Natl. Cancer Inst. 99, 742-743 (2007)
86. Sayin, V.I. et al. Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med. 6, 221ra15 (2014).
87. The α-Tocopherol β-Carotene Cancer Prevention Study Group. The effect of vitamin-E and β-carotene on the incidence of lung-cancer and other cancers in male smokers. N. Engl. J. Med. 330, 1029-1035 (1994)
88. Cheng, G. et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 72, 2634-2644 (2012)
89. Nazarewicz, R.R. et al. Does scavenging of mitochondrial superoxide attenuate cancer prosurvival signaling pathways? Antioxid. Redox Signal. 19, 344-349 (2013)
90. Snow, B.J. et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25, 1670-1674 (2010)
91. DeNicola, G.M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109 (2011).
92. Locasale, J.W. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat. Rev. Cancer 13, 572-583 (2013)
93. Ye, J. et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. (2014).
94. Nilsson, R. et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat. Commun. 5, 3128 (2014)
95. Glasauer, A., Sena, L.A., Diebold, L.P., Mazar, A.P. & Chandel, N.S. Targeting SOD1 reduces experimental non-small-cell lung cancer. J. Clin. Invest. 124, 117-128 (2014)
96. Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 10, 241-252 (2006)
97. Martin-Rufián, M. et al. Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. J. Mol. Med. (Berl.) 92, 277-290 (2014)
98. Raj, L. et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231-234 (2011)
99. Fesik, S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5, 876-885 (2005)
100. Murphy, M.P. & Smith, R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 47, 629-656 (2007)
101. Marrache, S., Pathak, R.K. & Dhar, S. Detouring of cisplatin to access mitochondrial genome for overcoming resistance. Proc. Natl. Acad. Sci. USA 111, 10444-10449 (2014)
102. Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628-632 (2014)